Ask about this productRelated genes to: RIOK2 antibody
- Gene:
- RIOK2 NIH gene
- Name:
- RIO kinase 2
- Previous symbol:
- -
- Synonyms:
- FLJ11159
- Chromosome:
- 5q15
- Locus Type:
- gene with protein product
- Date approved:
- 2003-06-25
- Date modifiied:
- 2016-10-05
Related products to: RIOK2 antibody
Related articles to: RIOK2 antibody
- Growth and carcass traits are key economic traits in beef cattle production, and identifying their associated genetic markers is crucial for improving breeding efficiency. Charolais cattle, as a superior beef breed, exhibit excellent performance in growth rate and meat production. The aim of this study was to utilize the preferred high-coverage whole-genome resequencing (hcWGS) as a replacement for single nucleotide polymorphism (SNP) chips to identify significant SNPs and candidate genes associated with growth (body weight, body height, cross height, body length, and chest measurement across different growth stages) and carcass traits (live backfat thickness and eye muscle area at 18 months) in 240 Charolais cattle, thereby providing guidance for beef cattle breeding. Through hcWGS (approximately 13× coverage) and quality control, 4,088,633 SNPs were identified and subsequently used for genetic analyses. Through FarmCPU-based genome-wide association studies, 196 potentially significant SNPs associated with growth traits and 29 SNPs with carcass traits were identified. Annotation analyses revealed 353 candidate genes (such as RBM33, KCTD17, PTHLH, RAC2, CHD6, TRDN, WBP1L, TLL2, CH25H, and ST13) linked to growth traits and 26 candidate genes linked to carcass traits (such as CHST11, LRRK2, RIOK2, and INTS10). Additionally, three SNPs (g.8674692C>G, g.54418624G>T, and g.71085551G>A) were validated via polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), enabling efficient marker-assisted selection. Furthermore, eight SNPs in the Acyl-CoA oxidase 1 (ACOX1) gene were found to be associated with growth and backfat thickness traits. These findings provide valuable preliminary insights into the genetic mechanisms underlying growth and carcass traits in Charolais cattle, facilitating genome-assisted breeding. - Source: PubMed
Publication date: 2025/11/25
Zhang FengWang ChengmeiShangguan AishaoSuo XiaojunChen MengjieTao HuJiang FanXu TianZhang NianHua ZaidongChai JinXiong Qi - Chronic psychological stress is a critical oncogenic factor of gastric cancer (GC). However, the mechanisms underlying stress-induced malignant progression remain largely unknown. Gut microbiota dysregulation is tightly associated with cancer development and metabolism. - Source: PubMed
Publication date: 2025/11/20
Zhao RuiyangLu YuyuanXu QixuanRen HuiguangLi HanghangGao JingwangCui HaoYuan ZhenCao BoWei Bo - Macrophage infection by the pathogenic bacteria Yersinia or mimic stimulation of lipopolysaccharide (LPS) and transforming growth factor-β-activated kinase 1 (TAK1) inhibitor or tumor necrosis factor (TNF) and TAK1 inhibitor induces caspase-8-mediated gasdermin D (GSDMD) cleavage and pyroptosis. However, the upstream regulator of caspase-8-dependent cleavage of GSDMD remains elusive. Here we show that Serine/threonine-protein kinase RIO2 (RIOK2) interacts with the Fas-associated protein with death domain (FADD) and is essential for caspase-8-driven GSDMD cleavage. RIOK2's kinase activity drives the transport of lysosome to ER through activating myosin II and thereby translocate FADD-RIPK1-caspase-8 complex from lysosome to ER. Importantly, RIOK2's ATPase activity enhances its binding to this complex and directly triggers caspase-8 and gasdermin D cleavage both at ER and in vitro. Furthermore, RIOK2-mediated pyroptosis enhances host defense against Yersinia infection. Thus, our findings define an upstream regulator of caspase-8-dependent pyroptosis, implying a role of organelle crosstalk in spatial cleavage of gasdermins. - Source: PubMed
Publication date: 2025/11/17
Ma MingtongWang FeiCui PengfeiZhang YingyingMa HanyuHe YifanCheng YuannaHuang JingpingWang JingxiangWu XiangyangYang HuaZheng RuijuanMa HaowenCai QianWang LinGe Baoxue - Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by rapid proliferation, invasiveness, therapeutic resistance, and an immunosuppressive tumor microenvironment. A subpopulation of glial stem-like cells (GSCs) within GBM tumors contributes significantly to tumor initiation, progression, and relapse, displaying remarkable adaptability to oxidative stress and metabolic reprogramming. Recent evidence implicates the atypical kinases RIOK1 and RIOK2 in promoting GBM growth and proliferation through their interaction with oncogenic pathways such as AKT and c-Myc. Concurrently, the redox-sensitive Nrf2/Keap1 axis regulates antioxidant defenses and supports GSC survival and chemoresistance. Additionally, aberrant activation of the canonical -catenin pathway in GSCs enhances their self-renewal, immune evasion, and resistance to standard therapies, particularly under oxidative stress conditions. This review integrates current knowledge on how redox homeostasis and key signaling pathways converge to sustain GSC maintenance and GBM malignancy. Finally, we discuss emerging redox-based therapeutic strategies designed to target GSC resilience, modulate the tumor immune microenvironment, and surmount treatment resistance. - Source: PubMed
Publication date: 2025/08/19
Esteban-Román Nadia FernandaTaddei ElisaCastro-Velázquez EdsonVillafuentes-Vidal LornaVelez-Herrera AlejandraRubio-Osornio MoisésRubio Carmen - RIOK2 is a promising therapeutic target in cancer due to its pivotal role in tumor progression. Based on our previously identified RIOK2 inhibitor CQ211, we conducted a comprehensive pharmacokinetic optimization campaign, leading to the discovery of CQ3196 as a potent and orally bioavailable RIOK2 inhibitor. CQ3196 demonstrates remarkable RIOK2 binding affinity, with a value of 14 nM, and exhibits potent proliferative inhibitory activities in gastric cancer cell lines. Furthermore, CQ3196 displays favorable PK properties, it achieves an AUC value of 3.5 × 10 μg/L·h following oral administration, ensuring sufficient drug exposure for therapeutic efficacy. Additionally, it achieves robust in vivo antitumor efficacy in an HGC-27 gastric cancer xenograft model. Oral administration of CQ3196 at 50 mg/kg resulted in a TGI value of 62.3%, highlighting its strong therapeutic potential. These compelling results underscore CQ3196 as a highly promising candidate for further development in RIOK2-targeted cancer therapy. - Source: PubMed
Publication date: 2025/08/14
Ma HaowenHuang ChaomingGu ManzhenWang YutingZhu ChenjunZeng HuiLi ZihaoXiong HuilanWu YanqingLai YuanhuiZhang Zhi-MinTan LiZhang ZhangCai Qian